HighMark Wealth Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

HighMark Wealth Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-895	Closed	-$67K	–	575
2022 Q2	$67K	Hold	895	–	–	0.05%	86
2022 Q1	$24K	Hold	895	–	–	0.02%	160
2021 Q4	$43K	Sell	895 -219	-20%	-$9.79K	0.03%	127
2021 Q3	$74K	Buy	1,114 +326	+41%	+$23.2K	0.05%	95
2021 Q2	$61K	Buy	788 +745	+1,733%	+$55.1K	0.04%	102
2021 Q1	$4K	Sell	43 -23	-35%	-$2.73K	﹤0.01%	378
2020 Q4	$8K	Sell	66 -327	-83%	-$35.8K	0.01%	278
2020 Q3	$34K	Buy	393 +317	+417%	+$22.1K	0.03%	124
2020 Q2	$5K	Buy	+76	New	+$4.38K	0.01%	319

HighMark Wealth Management's TPTX Position: Q3 2022 in Review

HighMark Wealth Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 895 shares — an estimated $67K sold.

HighMark Wealth Management first reported a position in TPTX in Q2 2020 and held it in 9 quarters. The position peaked at $74K in Q3 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

HighMark Wealth Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
HighMark Wealth Management sold 895 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $67K.
HighMark Wealth Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
HighMark Wealth Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $74K in Q3 2021.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on HighMark Wealth Management's 13F filing for Q3 2022, filed 21 Oct 2022.